Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions

Ruixue Chen, Guijuan Zhang, Yi Ma, Fengjie Bie, Hongxia Fan, Min MaEvidence-based 2017 · DOI

TL;DR

This study investigates the effectiveness of Ruyan Neixiao Cream (RYNXC), a traditional Chinese herbal formula, in treating mammary precancerous lesions. RYNXC demonstrated significant improvements in key physiological markers and reduced the progression of lesions in a rat model, suggesting its potential as a therapeutic agent. The research also identified fifteen key chemical constituents within RYNXC, providing a foundation for quality control and further pharmacological exploration.

What Problem Does This Paper Address?

Breast cancer remains a leading cause of cancer-related deaths in women, with precancerous lesions representing a critical stage in its development. Current treatments, like tamoxifen (TAM), have limitations and recurrence risks persist even after therapy. Traditional Chinese Medicine (TCM) offers a holistic approach, with historical use of herbal formulas for breast conditions. However, the pharmacological basis and chemical composition of many TCM formulas, like RYNXC, require rigorous scientific investigation to validate their efficacy and establish quality standards for broader clinical application. This paper aims to bridge this gap by evaluating RYNXC's in vivo effects on mammary precancerous lesions and characterizing its active components.

Methods

The researchers employed a multi-faceted approach combining in vivo animal studies with advanced analytical chemistry techniques.

  • Animal Model: A rat model of mammary precancerous lesions was induced using 7,12-Dimethylbenz[a]anthracene (DMBA) in combination with estrogen and progesterone. This is a standard method for creating such models.
  • Treatment Groups: Thirty-two Sprague-Dawley rats were divided into four groups: a blank control (BC), a mammary precancer model (MODEL), a tamoxifen-treated group (TAM), and the RYNXC-treated group.
  • Pharmacodynamic Evaluation: After 60 days of intervention, various physiological and pathological parameters were assessed. These included:
  • Microcirculation Perfusion: Measured in mammary tissues to assess blood flow.
  • Hemorheology: Evaluated hematocrit (HCT), fibrinogen (FIB), and erythrocyte aggregation index (EAI) to assess blood properties.
  • Organ Coefficients: Spleen, liver, and uterus coefficients were measured as indicators of systemic effects.
  • Pathological Observation: Hematoxylin-eosin (H&E) staining was used to examine mammary tissue for histological changes, specifically looking for the progression from hyperplasia to carcinoma.
  • Medicinal Chemistry: High-Performance Liquid Chromatography coupled with Mass Spectrometry (HPLC-MS) was utilized to separate, identify, and characterize the chemical constituents of RYNXC. This technique allows for the detection and tentative identification of multiple compounds within a complex herbal extract.

Datasets

Not discussed in the paper. The study relies on experimental data generated from the animal model and chemical analysis of the RYNXC extract.

Key Insights and Ideas

  • RYNXC as a Promising Therapeutic: The study strongly suggests RYNXC is an effective external treatment for mammary precancerous lesions, showing significant improvements in physiological markers and a reduction in lesion severity compared to the untreated model.
  • Synergistic Action of Herbal Components: The identification of fifteen diverse compounds (organic acids, tannin, alkaloid, volatile oil, anthraquinones, and flavonoids) highlights the complex, multi-component nature of RYNXC, hinting at potential synergistic interactions contributing to its therapeutic effects.
  • Beyond Tamoxifen: While TAM showed some improvement, RYNXC demonstrated comparable or even superior effects in certain parameters (e.g., HCT, spleen coefficient), suggesting it could be a viable alternative or adjunct therapy.
  • Importance of Quality Control: The detailed chemical characterization using HPLC-MS provides a crucial foundation for establishing quality control standards for RYNXC, ensuring consistency and efficacy in future clinical applications.

Key Results

  • Physiological Improvements: RYNXC treatment led to significant improvements in erythrocyte aggregation index (EAI), hematocrit (HCT), fibrinogen (FIB), spleen coefficient, and uterus coefficient compared to the MODEL group.
  • Pathological Findings: In the MODEL group, ductal carcinoma in situ was observed. In contrast, RYNXC and TAM groups showed atypical hyperplasia, indicating a halt or reversal in lesion progression.
  • Chemical Profiling: Fifteen compounds were tentatively identified in RYNXC, including gallic acid, cianidanol, chlorogenic acid, tetrahydropalmatine, rosmarinic acid, quercetin, luteolin, eugenol, kaempferol, apigenin, aloe-emodin, rhein, emodin, 11-keto-β-boswellic acid (KBA), and 3-acetyl-11-keto-β-boswellic acid (AKBA).

Limitations and Future Work

  • Limitations:
    • The study was conducted on an animal model, and direct translation of these findings to human efficacy requires further clinical trials.
  • While fifteen compounds were identified, their specific individual contributions to the overall therapeutic effect of RYNXC were not fully elucidated.
  • The exact mechanisms of action for RYNXC and its constituents were not deeply explored.
  • Future Work:
    • Further investigation into the specific pharmacological mechanisms of RYNXC and its identified compounds is warranted.
  • Clinical trials are necessary to validate the efficacy and safety of RYNXC in human patients with mammary precancerous lesions.
  • Developing more precise quality control methods based on the identified chemical markers would be beneficial.

Summary updated

Abstract

Ruyan Neixiao Cream (RYNXC) is a traditional Chinese herbal formula for treating mammary precancerous disease. This study was carried out to investigate in vivo anticancer effect of RYNXC and multiple constituents. 32 virginal Sprague-Dawley rats were randomly divided into blank control group (BC), mammary precancer models group (MODEL), tamoxifen group (TAM), and Ruyan Neixiao Cream group (RYNXC). TAM was intervened by tamoxifen; RYNXC was intervened by Ruyan Neixiao Cream. The chromatographic separation was performed by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS). RYNXC showed significant improvement in erythrocyte aggregation index (EAI), hematocrit (HCT), fibrinogen (FIB), spleen coefficient, and uterus coefficient compared with MODEL. In RYNXC and TAM groups, atypical hyperplasia was observed in pathological mammary tissues; meanwhile in MODEL group, ductal carcinoma was observed in situ. Moreover, fifteen compounds were characterized according to HPLC-MS data, including organic acids, tannin, alkaloid, volatile oil, anthraquinones, and flavonoids. The study suggests that RYNXC was an effective Chinese herbal formula for mammary precancerous lesions and provides a scientific basis for the quality standard and the pharmacology of RYNXC. It will be beneficial to the future clinical application of RYNXC.
BibTeX
@inproceedings{chen2017pharmacodynamics,
  author = {Ruixue Chen and Guijuan Zhang and Yi Ma and Fengjie Bie and Hongxia Fan and Min Ma},
  title = {{Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions}},
  booktitle = {Evidence-based},
  year = {2017},
  doi = {10.1155/2017/6235027},
}
Figure